Abstract:This study highlights the considerable regulatory role of LINC01419 in the metabolism of HCC. The newly identified LINC01419/YBX1‐PDK1 axis constitutes a valuable target. Hepatic‐specific delivery of GalNAc‐siLINC01419 presents a promising therapeutic strategy for HCC. . Metabolic reprogramming provides the necessary energy for the development of malignant tumours and is emerging as a novel tumour treatment strategy. However, the widespread expression of metabolic enzymes in diverse cell types makes the development of specific drugs that target cancer cells without affecting normal cellular functions challenging. Accumulating evidence has demonstrated the essential roles of long non‐coding RNAs (lncRNAs) in the regulatory network associated with glucose metabolism in tumour cells. The mechanism and therapeutic potential of cancer‐specific lncRNAs in modulating tumour glucose metabolism warrant in‐depth exploration. Here we revealed that glucose‐induced LINC01419 promoted the growth and metastasis of HCC cells by driving metabolic reprogramming. Mechanistically, LINC01419 directly interacted with Y‐box binding protein 1 (YBX1) in the cytoplasm and facilitated its binding to PDK1 mRNA, thus enhancing PDK1 mRNA stability and increasing lactate production. Furthermore, YY1 contributed to the transcriptional activation of LINC01419 in HCC under high‐glucose conditions. Notably, administration of an N‐acetylgalactosamine (GalNAc)‐conjugated siRNA specifically targeting LINC01419 markedly retarded the growth of orthotopic xenograft tumours. These findings provide evidence for an unprecedented regulatory mechanism of LINC01419 involving metabolic reprogramming in human cancer. The newly identified LINC01419/YBX1‐PDK1 axis may represent a promising therapeutic target for HCC. Moreover, GalNAc‐siLINC01419 holds significant potential for clinical application. Key points This study highlights the considerable regulatory role of LINC01419 in the metabolism of HCC. The newly identified LINC01419/YBX1‐PDK1 axis constitutes a valuable target. Hepatic‐specific delivery of GalNAc‐siLINC01419 presents a promising therapeutic strategy for HCC.

mcPGK1-dependent mitochondrial import of PGK1 promotes metabolic reprogramming and self-renewal of liver TICs

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis

Atg5-independent Autophagy Regulates Mitochondrial Clearance and is Essential for Ipsc Reprogramming

PGC1α Promotes Cholangiocarcinoma Metastasis by Upregulating PDHA1 and MPC1 Expression to Reverse the Warburg Effect.

Thymidine Kinase 1 Drives Hepatocellular Carcinoma in Enzyme-Dependent and -Independent Manners.

Mitochondrial Mir-181A-5p Promotes Glucose Metabolism Reprogramming in Liver Cancer by Regulating the Electron Transport Chain.

PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process

O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth

The Oncogenic Role and Regulatory Mechanism of PGK1 in Human Non-Small Cell Lung Cancer

TPO-Induced Metabolic Reprogramming Drives Liver Metastasis of Colorectal Cancer CD110+ Tumor-Initiating Cells.

LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway

Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner

Glucose‐induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma

Gankyrin and TIGAR Cooperatively Accelerate Glucose Metabolism Toward the PPP and TCA Cycle in Hepatocellular Carcinoma

ALKBH5‐induced Circular RNA NRIP1 Promotes Glycolysis in Thyroid Cancer Cells by Targeting PKM2

Nuclear-encoded lncRNA MALAT1 epigenetically controls metabolic reprogramming in hepatocellular carcinoma cells through the mitophagy pathway

Energy stress-induced circDDX21 promotes glycolysis and facilitates hepatocellular carcinogenesis

TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer

Targeting PGC1α to wrestle cancer: a compelling therapeutic opportunity

PGK1 Promotes NSCLC Progression by Enhancing Aerobic Glycolysis and Activating AKT/ERK Signaling Pathway